1. Scrip
  2. >>Business
  3. >>Financing

Arix To Nurture Next Generation Biotechs After UK IPO

 
• By John Davis

The supply of "permanent" capital and the desire to be involved operationally in new life science companies are some of the aims of Arix Bioscience, a UK company aiming to float on the London Stock Exchange, possibly by the end of this month.

Arix Bioscience
(From Left) Arix's Sir Chris Evans, Joe Anderson and Jonathan Peacock

A year-old healthcare and life science operating company, Arix Bioscience PLC, has announced its intention to raise up to £100m ($125m) in an IPO on the main market of the London Stock Exchange, driven by what it sees as a burgeoning demand from universities, small companies and research accelerators for financial and operational support to develop a veritable flood of good ideas for new therapeutics.

Life science initial public offerings (IPOs) on the UK Stock Exchange have been few and far between over past months,...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Financing

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

Finance Watch: Just As The XBI Began Turnaround, Trump Upped MFN Pricing Threats

 
• By Mandy Jackson

Public Company Edition: The XBI fund attempted a correction midway through the week ending Aug. 1, but President Trump’s most favored nation drug pricing threats tanked valuations again. In financings, Leads Biolabs raised $189m in a Hong Kong IPO and Abivax closed a $747.5m FOPO.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Frazier Life Sciences Raises $1.3bn To Fund Start-Ups Through Value-Creating Data

 
• By Mandy Jackson

Frazier Life Sciences will invest 40%-50% of its new venture capital fund in new biopharma companies financed to develop preclinical drug candidates through clinical proof of concept and, hopefully, M&A.

More from Business

BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam

 
• By Manas Mishra

Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Amgen Plans AI Investment Amid Strong Sales Growth

 
• By Alaric DeArment

CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.